BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,463 | -12.5% | 33,540 | -13.0% | 0.02% | -13.6% |
| Q2 2023 | $271,322 | -18.5% | 38,540 | -3.5% | 0.02% | -21.4% |
| Q1 2023 | $333,100 | +72788.4% | 39,940 | +0.4% | 0.03% | -33.3% |
| Q4 2022 | $457 | -99.9% | 39,800 | +1.9% | 0.04% | -17.6% |
| Q3 2022 | $492,000 | +4.7% | 39,050 | -12.1% | 0.05% | +21.4% |
| Q2 2022 | $470,000 | -26.8% | 44,450 | +12.5% | 0.04% | -19.2% |
| Q1 2022 | $642,000 | +2.7% | 39,500 | -12.5% | 0.05% | +2.0% |
| Q4 2021 | $625,000 | +4.9% | 45,125 | +8.8% | 0.05% | -16.4% |
| Q3 2021 | $596,000 | +44.0% | 41,475 | +58.3% | 0.06% | +45.2% |
| Q2 2021 | $414,000 | +123.8% | 26,200 | +44.0% | 0.04% | +121.1% |
| Q1 2021 | $185,000 | – | 18,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |